1623 Capital’s Novavax NVAX Stock Holding History

1623 Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,095	Closed	-$227K	–	67
2021 Q3	$227K	Buy	+1,095	New	+$241K	0.09%	69

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

1623 Capital's NVAX Position: Q4 2021 in Review

1623 Capital sold out of Novavax (NVAX) in Q4 2021, closing a stake of 1,095 shares — an estimated $227K sold.

1623 Capital first reported a position in NVAX in Q3 2021 and held it in 1 quarter. The position peaked at $227K in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

1623 Capital reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
1623 Capital sold 1,095 Novavax shares in Q4 2021, an estimated $227K.
1623 Capital first reported a position in Novavax in Q3 2021 and held it in 1 quarter.
1623 Capital's Novavax position peaked at $227K in Q3 2021.
429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on 1623 Capital's 13F filing for Q4 2021, filed 11 Feb 2022.